Cargando…
Clinical and therapeutic implications of BRAF fusions in histiocytic disorders
Autores principales: | Zanwar, Saurabh, Abeykoon, Jithma P., Dasari, Surendra, Ravindran, Aishwarya, Young, Jason R., Acosta-Medina, Aldo A., Rech, Karen L., Schwartz, Jonathan, Mangold, Aaron, Rosenthal, Allison, Bennani, N. Nora, Shah, Mithun V., Morlote, Diana, Goyal, Gaurav, Go, Ronald S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240055/ https://www.ncbi.nlm.nih.gov/pubmed/35764604 http://dx.doi.org/10.1038/s41408-022-00693-7 |
Ejemplares similares
-
Sirolimus as frontline therapy for PTEN-mutated histiocytic sarcoma
por: Chohan, Karan L., et al.
Publicado: (2022) -
Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma
por: Zanwar, Saurabh, et al.
Publicado: (2022) -
Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience
por: Goyal, Gaurav, et al.
Publicado: (2022) -
P1049: CHARACTERISTICS AND OUTCOMES OF CARDIOVASCULAR INVOLVEMENT IN ERDHEIM-CHESTER DISEASE
por: Tawfiq, Reema, et al.
Publicado: (2023) -
Long-term outcomes among adults with Langerhans cell histiocytosis
por: Goyal, Gaurav, et al.
Publicado: (2023)